MSACL 2023 Industry Workshop Presentation *This Podium Presentation is occuring in the context of an Industry Workshop that starts at the time below. Its actual start time may be up to 40 minutes later, depending on order of presentation if there are multiple presentations planned by the workshop host. Workshop Host: Thermo Fisher Scientific Day: Wednesday April 5 Time: 7:00* Location: Steinbeck 1

Advancing ICP-MS to clinical testing: A novel highly sensitive diagnostic platform for early detection and therapeutic monitoring of bone metabolic disorders
	Michael Lutz, PhD Osteolabs GmbH
Presenter Bio: Dr. Michael Lutz is a seasoned international life sciences executive with a significant wealth of entrepreneurial and start-up experience from the diagnostic and biotechnology industries. Michael is supporting Osteolabs since a number of years related to strategic, business and clinical development. In the past, Michael served as CEO at HepaRegeniX, a clinical stage biotech company in the field of advanced liver diseases. Before that, he was CEO of several Life Sciences companies which he successfully established or built-up to a successful exit. Michael holds a Ph.D in bioorganic chemistry from the ETH Zurich (Switzerland) and currently also serves on the Board of several other life sciences companies in Germany, the UK, Italy and Denmark.

Clinical studies have demonstrated that the naturally occurring stable Ca isotope ratio of 44Ca/42Ca (δ44/42Ca) in serum and urine is a significant and non-invasive predictor of bone mineral balance (BMB). This has led to successful clinical validation and launch of the first clinical diagnostic test based on a Calcium Isotope Fractionation ICP-MS method for early detection and therapeutic monitoring of osteoporosis (OsteoTest). From routine testing of > 3,500 OsteoTest samples to date from several EU countries the method may have wider applicational use with respect to secondary osteoporotic effects, as well as Chronic Kidney Disease and related vascular calcification. The presenter will also discuss first feasibility studies shown to demonstrate potential use of the underlying technology for bone metastases related to prostate cancer.